Desmoid tumor (aggressive fibromatosis) is a soft tissue neoplasm arising from fibroblasts and myofibroblasts that is locally aggressive but does not metastasize. It accounts for approximately 3% of all soft tissue tumors. Most common between ages 15-60 (peak: 25-35 years) with slight female predominance. It shows three main location patterns: extra-abdominal (shoulder, hip, extremities — musculoaponeurotic location), abdominal wall (rectus abdominis, post-pregnancy), and intra-abdominal (mesentery — FAP/Gardner syndrome associated). Beta-catenin/CTNNB1 gene mutation is fundamental to pathogenesis. Local recurrence rate is high (20-40%) but distant metastasis does not occur.
Age Range
15-40
Peak Age
30
Gender
Female predominant
Prevalence
Uncommon
Desmoid tumor is a clonal fibroblastic/myofibroblastic proliferation characterized by inappropriate activation of the Wnt/beta-catenin signaling pathway. CTNNB1 gene mutation (encoding beta-catenin) is detected in 85-90% of cases, and nuclear beta-catenin accumulation is used in immunohistochemical diagnosis. The tumor contains abundant collagen fibrils and variable numbers of fibroblasts/myofibroblasts; the collagen/cell ratio directly determines tumor biology and MRI signal. Collagen-rich regions produce low T2 signal (organized collagen fibers have short T2 relaxation), cellular regions produce high T2 signal — therefore, T2 signal of desmoid tumor is heterogeneous and depends on collagen content. This feature is also critical in treatment response monitoring: when collagen increases and cellularity decreases with treatment, T2 signal decreases. The locally aggressive behavior of the tumor reflects its infiltrative growth pattern along fascial planes and muscle fibers — high rate of positive surgical margins is the fundamental reason for high recurrence risk.
Low-signal bands within the mass on T2-weighted sequences ('band of low signal') due to collagen deposition are highly characteristic of desmoid tumor. These bands reflect the short T2 relaxation of organized collagen fibers and help distinguish the tumor from other soft tissue masses. The volumetric ratio of collagen bands indicates tumor maturity.
On T2-weighted sequences, desmoid tumor shows heterogeneous signal. Collagen-dominant areas show low T2 signal ('band of low signal' — dark bands), cellular/myxoid areas show high T2 signal. This mixed pattern is highly characteristic of desmoid tumor. Mature, collagen-heavy tumors show predominantly low T2 signal; active cellular tumors show predominantly high T2 signal. T2 signal change is the most reliable MRI indicator of treatment response.
Report Sentence
On T2-weighted sequences, the mass demonstrates heterogeneous signal with low-signal collagenous bands and high-signal cellular areas, consistent with desmoid tumor (aggressive fibromatosis).
On T1-weighted sequences, desmoid tumor shows isointense or slightly hypointense signal relative to muscle. Homogeneous or mildly heterogeneous T1 signal is seen. Collagen-dominant areas may be hypointense, cellular areas isointense. Infiltration between muscle fibers may be seen as loss of boundary between muscle and tumor on T1.
Report Sentence
On T1-weighted sequences, a musculoaponeurotic mass isointense to muscle is seen.
On STIR sequences, desmoid tumor shows variable signal depending on activity status. Active (cellular) tumors show marked hyperintensity; inactive (collagen-dominant) tumors show low-to-intermediate signal. Change in STIR signal is one of the most reliable indicators of treatment response — signal decrease with treatment reflects maturation/collagenization, signal increase reflects activation. Peritumoral edema may be visible on STIR and suggests active growth.
Report Sentence
On STIR sequences, the mass shows variable signal, with signal intensity reflecting tumor activity.
Post-contrast, desmoid tumor shows moderate-to-marked enhancement. Enhancement is usually homogeneous or mildly heterogeneous. Since necrosis is rare, non-enhancing areas are generally absent (unlike high-grade sarcomas). Less enhancement in collagen-dominant areas, more enhancement in cellular areas is expected. Changes in contrast pattern over time may reflect treatment response.
Report Sentence
On post-contrast images, the mass shows moderate-to-marked enhancement without necrotic areas.
On DWI, desmoid tumor shows variable diffusion characteristics. Cellular active tumors show moderate diffusion restriction (intermediate-to-low ADC), collagen-dominant inactive tumors show no diffusion restriction (high ADC reflects that collagen fibrils do not impede free water diffusion). DWI is used together with T2 signal in treatment response monitoring — ADC increase is expected after successful treatment.
Report Sentence
On DWI, the mass shows variable diffusion characteristics with ADC values correlating with tumor activity and cellularity.
On CT, desmoid tumor appears as a well or poorly defined soft tissue mass isodense or slightly hypodense to muscle. Post-contrast shows moderate-to-marked enhancement. Calcification is rare. CT's role is limited but valuable in evaluating bowel involvement and mesenteric vascular involvement in abdominal/pelvic desmoid tumors, detecting bone invasion, and FAP screening (colonoscopy planning).
Report Sentence
On CT, a musculoaponeurotic enhancing soft tissue mass is seen.
On US, desmoid tumor typically appears as a hypoechoic or heterogeneous echogenicity mass with irregular margins. Collagen-dominant areas may appear hyperechoic, cellular areas hypoechoic. Posterior acoustic shadowing may be seen in collagen-heavy tumors. US may be used as primary imaging in abdominal wall desmoid tumors but MRI is preferred for deep-seated lesions.
Report Sentence
On US, a mass of heterogeneous echogenicity is seen in musculoaponeurotic location.
Criteria
Trunk (shoulder, hip) or extremity location, in musculoaponeurotic structures, infiltrative growth along fascia and muscle
Distinct Features
Most common type (50-60%). In young adults. High positive surgical margin and recurrence rate. Extension along fascial planes complicates surgical planning. Active surveillance (watch and wait) has been adopted as primary approach in recent years.
Criteria
Within rectus abdominis or oblique muscles, in post-pregnancy or surgical (cesarean) scar region
Distinct Features
Strong pregnancy and estrogen association. Common in young women. May arise in cesarean scar region. Primary evaluation possible with US. MRI for extent and surgical planning. Tamoxifen or NSAID treatment options.
Criteria
Mesenteric or retroperitoneal location, strong association with FAP/Gardner syndrome, potential for bowel and vascular encasement
Distinct Features
Develops in 10-20% of FAP patients. APC gene mutation screening mandatory. Risk of bowel obstruction, ureteral compression, mesenteric ischemia. Surgery mostly contraindicated (high morbidity). Medical treatment (tamoxifen, sulindac, chemotherapeutic agents) preferred. Spontaneous regression possible.
Distinguishing Feature
Soft tissue sarcoma (UPS) contains necrosis and marked hemorrhage, heterogeneous enhancement + necrotic areas, high grade, metastatic potential; desmoid tumor necrosis rare, homogeneous enhancement, no metastasis, collagenous low-signal bands on T2
Distinguishing Feature
Schwannoma nerve-associated, target sign, split-fat sign, encapsulated; desmoid tumor musculoaponeurotic, no nerve association, T2 collagenous bands, infiltrative margin
Distinguishing Feature
Liposarcoma contains fat signal (T1 hyperintense component), incomplete suppression on fat suppression; desmoid tumor contains no fat component, T1 isointense to muscle, collagen-based T2 heterogeneity
Distinguishing Feature
Fibrous dysplasia intraosseous lesion, ground-glass density on CT, bone deformity; desmoid tumor soft tissue mass, not intraosseous, collagenous T2 bands, musculoaponeurotic location
Urgency
semi-urgentManagement
active surveillance (first-line); medical therapy (NSAIDs, tamoxifen, chemotherapy); surgery reserved for progressive/symptomatic; multidisciplinary sarcoma teamBiopsy
NeededFollow-up
MRI every 3-6 months initially, assess T2 signal change for treatment response; lifelong follow-up for recurrence; APC gene testing and colonoscopy for mesenteric typeThe management paradigm for desmoid tumor has changed significantly in recent years. Active surveillance (watch and wait) is recommended as the first approach — spontaneous stabilization or regression is seen in 20-30% of patients. In case of progression, medical therapy (sulindac, tamoxifen, vinblastine+methotrexate, sorafenib, nirogacestat) is applied. Surgery is the last resort due to high recurrence rate (20-40%) and functional morbidity. Biopsy is mandatory for diagnostic confirmation — nuclear beta-catenin positivity supports the diagnosis. In MRI follow-up, T2 signal change is an earlier and more reliable response indicator than size change. FAP/Gardner syndrome screening (APC gene test + colonoscopy) is mandatory for mesenteric desmoid tumors. Counseling is recommended for women planning pregnancy due to hormonal association.
Treatment is controversial: active surveillance (spontaneous regression possible), surgical excision, medical therapy (anti-estrogen, NSAID, chemotherapy), or radiotherapy are options. Local recurrence rate after surgery is 20-40%. Mesenteric desmoid is common in FAP (familial adenomatous polyposis) patients — APC gene mutation should be screened.